STAT Plus: A new FTC policy may alter the calculus for some pharma M&A deals

The shift comes after the FTC found a high failure rate involving divested complex medicines.

Original Article: STAT Plus: A new FTC policy may alter the calculus for some pharma M&A deals

More From BioPortfolio on "STAT Plus: A new FTC policy may alter the calculus for some pharma M&A deals"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications